12 results about "OD - Optical density" patented technology

The invention belongs to the technical field of sugar alcohol, and particularly relates to a method for quickly detecting bacteriophage in fermentation liquor, which comprises the following steps: centrifuging the fermentation liquor to obtain supernate, boiling the supernate in a boiling water bath for 2-5 minutes to obtain boiled liquor, visually comparing the turbidity difference between the supernate and the boiled liquor, and if the supernate is clear, judging whether the bacteriophage is in the boiling state or not. If the boiled liquid is turbid, the fermentation liquid is polluted by the bacteriophage; if the turbidity difference between the supernatant and the boiled liquid is not obvious, respectively measuring OD650 optical density values of the supernatant and the boiled liquid by using a spectrophotometer, comparing the optical density detection values, and if the difference between the two is not more than 0.5, indicating that the fermentation liquor is not infected by the bacteriophage; if the difference is greater than 0.5, the fermentation liquor is polluted by the bacteriophage. According to the method, whether the fermentation liquor is polluted by the bacteriophage or not is judged by visually comparing the turbidity difference before and after the supernate obtained after the fermentation liquor is centrifuged is heated and further verifying the difference of optical density values by using the spectrophotometer, and the method has the characteristics of rapidness, convenience and accuracy.

Provided herein are methods for the production of a vector with a size of at least 16 kb from bacterial cells comprising the consecutive steps of a) obtaining bacterial cells comprising a vector with a size of at least 16 kb, comprising an inducible origin of replication, b) inoculating culture medium with the bacterial cells comprising the vector, c) culturing the bacterial cells in the culture medium, d) adding one or more inducers of said inducible origin of replication to the culture medium when the bacterial culture has reached an optical density at 600 nm (OD600) of at least 20, e) further culturing the bacterial cells in the culture medium, f) optionally separating the bacterial cells from the culture medium, and g) recovering the plasmid from the bacterial cells. Also provided herein are vectors with a size of at least 16 kb comprising an inducible origin of replication for use in such methods.

Accurate hydration measurement is crucial for health. This patent presents a non-invasive method for quantifying hydration in tissues and bloodstream using heartbeat-based optical density (OD) analysis. By employing LEDs at specific wavelengths for water and blood OD measurements and correcting for melanin interference, this method calculates hydration as the ratio of water OD to blood OD. The technique offers precise, rapid, and minimally invasive hydration assessment, addressing traditional method limitations. This approach is suitable for wearable or stand-alone devices, enhancing health monitoring and personalized hydration strategies.

The utility model discloses an intelligent bioreactor integrated with a multi-parameter biochemical analysis function. The intelligent bioreactor comprises an optical detection module, an electrochemical sensor module and an overflow pool biochemical detection module, the optical detection module adopts a transmission-type optical measurement principle and is used for measuring the optical density of the culture solution; the electrochemical sensor module adopts an electrochemical principle and is used for detecting the concentration of at least 10 metabolites in the culture solution; the overflow pool biochemical detection module adopts an ion selective electrode principle and is used for simultaneously detecting the concentrations and pH values of NH4 < + >, K < + >, Na < + > and Ca < 2 + > ions in the culture solution; the three modules are sequentially connected through fluid channels to form a complete detection flow path.

This patent describes an advanced method for the accurate optical quantification of antioxidant carotenoids in biological tissues. The method addresses interference from melanin and hemoglobin through comprehensive correction techniques. It involves creating a tangent line for melanin correction using absorbance values at 650 nm and 700 nm, measuring the corrected optical density (OD) of carotenoids at 488 nm, measuring the corrected OD of blood at 577 nm, converting the Blood OD from 577 nm to 488 nm using oxyhemoglobin and deoxyhemoglobin extinction coefficients, and subtracting the Blood OD from the Carotenoid OD to obtain the final Carotenoid OD. This innovative approach provides reliable, non-invasive, and precise measurements of carotenoid levels in tissues, facilitating improved health assessments and personalized nutrition strategies.

The invention provides a breast cancer auxiliary diagnosis method and system based on virtual staining, and the method comprises the steps: firstly obtaining an HE staining section, carrying out the enhancement preprocessing, and generating an ER / PR / HER2 virtual IHC image through a GAN-based virtual staining model; on the basis of a DAB channel obtained through color deconvolution integral separation and cancerization areas and cell nucleus instance segmentation results obtained on the virtual IHC and / or HE images, indexes such as nucleus density, nucleus morphology, ER / PR positive cell nucleus proportion, HER2 membrane continuity / coverage rate, positive area proportion and average optical density are calculated, and a superposition and structuring report is generated. According to the method, combined losses such as positive region consistency, membrane ring continuity, nuclear grade consistency and grading alignment are introduced in the training stage, a nuclear density self-adaptive activation function is adopted, and the consistency and robustness of virtual dyeing and quantitative evaluation are improved. IHC reagents can be reduced, the period is shortened, and the cross-section comparison difficulty is reduced.

The embodiment discloses an optical density measurement and testing including a purification device that separates live cancer cells from dead and non-cancer cells of a microbiology sample. A drug addition device and a drug dosage sequencer introduce controlled dosages of at least one drug treatment into the live cancer cells. An optical density measurement device with an optical sensor captures high-resolution images of the live cells at predetermined intervals, and an optical spectrophotometric reader quantifies cell populations following treatment. A flow cytometry device measures fluorescent intensities of immune checkpoint markers and tumor antigens to generate immune system activation profiles. A processor subsystem analyzes cell death rates and immune responses to create integrated drug response profiles, and a computer application compares these results with patient-specific genetic and clinical data to produce personalized treatment recommendations.

The invention relates to the technical field of detection, and particularly discloses a small molecule compound detection method and application thereof. The small molecule compound detection method comprises the following steps: (1) enriching and extracting to-be-detected small molecule compounds in a to-be-detected sample to obtain a to-be-detected solution; (2) obtaining a magnetic nano enzyme coated with an antibody; (3) mixing the two solutions, performing magnetic separation, and redissolving to obtain a to-be-detected particle solution; (4) in the MetaSPR chip detection hole coated with the to-be-detected small molecule compound hapten, detecting the optical density of the blank detection liquid and the optical density of the to-be-detected particle solution after incubation, and calculating the concentration value I of the to-be-detected small molecule compound according to the optical density difference between the blank detection liquid and the to-be-detected particle solution; and (5) calculating the solution of which the end point optical density is detected through a catalytic colorimetric method to obtain a concentration numerical value II of the to-be-detected small molecule compound. The dual-mode detection method disclosed by the invention is simple and convenient to operate, high in accuracy, low in detection limit, stable in performance, high in detection flux and suitable for safe and rapid screening of food.

The invention provides an application of SERPINB10 protein as a diagnostic marker in preparation of a diagnostic kit for identifying eosinophilic esophagitis and reflux esophagitis. The invention also provides an application of the SERPINB10 protein in preparation of a product for differential diagnosis of eosinophilic esophagitis and reflux esophagitis. The invention also provides application of the reagent for detecting the SERPINB10 protein in preparation of a diagnostic kit for identifying eosinophilic esophagitis and reflux esophagitis. When the SERPINB10 protein immunohistochemical detection integral optical density of the esophageal tissue sample of the subject is greater than or equal to 41666, it is shown that the patient suffers from eosinophilic esophagitis, and otherwise, the patient suffers from reflux esophagitis. The invention establishes an EoE diagnosis and differential diagnosis system which is objective, accurate and low in missed diagnosis rate.

The present invention provides an optical density based non-invasive, field usable method for the detection of pregnancy in healthy ruminant livestock using naturally micturated urine. The present invention also provides a colorimetric kit for detection of pregnancy in ruminants livestock. The test also helps in differentiating between pregnant and non-pregnant ruminant females using urine samples.

The invention discloses a method for determining the dilution ratio of a biochemical super-linear sample based on reaction curve characteristics. The method comprises the following steps: after a biochemical reaction begins, according to a point P corresponding to a first optical density value exceeding 2.0000 displayed by a biochemical analyzer, determining the optimal dilution ratio N of the biochemical super-linear sample according to the following correspondence: the point P is 19-24, and the N is 2; the P point is 17-18, and the N is 3; the P point is 15-16, and the N is 4; the P point is 14, and the N is 5; the P point is 13, and the N is 8; the P point is 12, and the N is 25; wherein the P point is a reading point for the biochemical analyzer to read the OD value every 18 seconds. The method can quickly and automatically calculate the optimal dilution ratio required for generating the super-linear sample in the first detection, so that the number of times of repeated detection is remarkably reduced, the working efficiency is improved, and precious reagents and samples are saved.

The application provides use of SERPINB10 protein as a diagnostic marker in preparation of a diagnostic kit for differentiating eosinophilic esophagitis from reflux esophagitis. The application also provides use of SERPINB10 protein in preparation of a product for differential diagnosis of eosinophilic esophagitis and reflux esophagitis. The application also provides use of a reagent for detecting SERPINB10 protein in preparation of a diagnostic kit for differentiating eosinophilic esophagitis from reflux esophagitis. When the integral optical density of SERPINB10 protein immunohistochemical detection of an esophageal tissue sample of a subject is greater than or equal to 41666, it shows that the patient has eosinophilic esophagitis, and otherwise, the patient has reflux esophagitis. The application establishes an objective, accurate and low-missed-diagnosis-rate EoE diagnosis and differential diagnosis system.